Targeting Tumor-Associated Macrophages in Cancer.,Trends in Immunology

当前位置： X-MOL 学术 › Trends Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Targeting Tumor-Associated Macrophages in Cancer.
Trends in Immunology ( IF 13.1 ) Pub Date : 2019-03-17 , DOI: 10.1016/j.it.2019.02.003
Paulina Pathria ₁ , Tiani L Louis ₁ , Judith A Varner ₂

Affiliation

Macrophages are phagocytes that serve as a first line of defense against pathogenic insults to tissues. These innate immune cells mount proinflammatory responses to pathogens and repair damaged tissues. However, tumor-associated macrophages (TAMs) express cytokines and chemokines that can suppress antitumor immunity and promote tumor progression. Preclinical studies have identified crucial pathways regulating the recruitment, polarization, and metabolism of TAMs during tumor progression. Moreover, novel therapeutics targeting these pathways can indirectly stimulate cytotoxic T cell activation and recruitment, and synergize with checkpoint inhibitors, chemotherapy and/or radiation therapy in preclinical studies. Thus, clinical trials with therapeutic agents that promote phagocytosis or suppress survival, proliferation, trafficking, or polarization of TAMs are currently underway. These early results offer the promise of improved cancer outcomes.

中文翻译：

针对肿瘤中与肿瘤相关的巨噬细胞。

巨噬细胞是吞噬细胞，可作为抵御组织致病性侵害的第一道防线。这些先天免疫细胞对病原体产生促炎反应并修复受损的组织。但是，肿瘤相关的巨噬细胞（TAM）表达的细胞因子和趋化因子可以抑制抗肿瘤免疫力并促进肿瘤进展。临床前研究已经确定了在肿瘤进展过程中调节TAM募集，极化和代谢的关键途径。此外，在临床前研究中，靶向这些途径的新型疗法可以间接刺激细胞毒性T细胞的活化和募集，并与检查点抑制剂，化学疗法和/或放射疗法协同作用。因此，使用可促进吞噬作用或抑制生存，增殖，贩运，或TAM的极化目前正在进行中。这些早期结果为改善癌症预后提供了希望。

更新日期：2019-03-17

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南